A strain of Bifidobacterium breve that can relieve rheumatoid arthritis and its application

A Bifidobacterium breve, rheumatoid technology, applied in the field of microorganisms, can solve the problems of lack and research, and achieve the effect of relieving rheumatoid arthritis

Active Publication Date: 2022-07-22
JIANGNAN UNIV
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, some progress has been made in the prevention and / or treatment of rheumatoid arthritis. Inflammation, however, the Bifidobacterium bifidum KCTC13474BP relieves rheumatoid arthritis, mainly focusing on the anti-inflammatory effect in vitro cells and the inhibition of rheumatoid arthritis autoantibodies, and there is still a lack of research on other indicators

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A strain of Bifidobacterium breve that can relieve rheumatoid arthritis and its application
  • A strain of Bifidobacterium breve that can relieve rheumatoid arthritis and its application
  • A strain of Bifidobacterium breve that can relieve rheumatoid arthritis and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Example 1: Screening and strain identification of Bifidobacterium breve CCFM1078

[0061] 1. Filter

[0062] Fecal samples from healthy infants from the Wuxi area were stored in a -80°C freezer in 30% glycerol. After the samples were taken out and thawed at low temperature, 0.5mL samples were mixed and added to 4.5mL, and 0.9g / 100mL normal saline containing 0.05g / 100mL cysteine ​​was used for gradient dilution. On MRS solid medium containing 0.05g / 100mL cysteine, cultured at 37°C for 48h, pick typical colonies on MRS solid medium for streak purification, pick a single colony and transfer to MRS liquid medium (containing 0.05 g / 100 mL cysteine), and the cultured cells were stored in 30% glycerol to obtain strain CCFM1078.

[0063] 2. Identification

[0064] The genome of CCFM1078 was extracted, and the 16S rDNA of CCFM1078 was amplified and sequenced (by Huada Gene Technology Co., Ltd., wherein the nucleotide sequence amplified by the 16S rDNA of CCFM1078 was shown in...

Embodiment 2

[0067] Example 2: Cultivation of Bifidobacterium breve CCFM1078

[0068] The Bifidobacterium breve CCFM1078 obtained in Example 1 was inserted into MRS solid medium (containing 0.05g / 100mL cysteine) and cultivated in an anaerobic incubator at 37°C for 48h, and the colonies were observed. The colonies are milky white, with smooth surface and rounded protrusions.

[0069] The Bifidobacterium breve CCFM1078 obtained in Example 1 was inserted into MRS liquid medium (containing 0.05g / 100mL cysteine) and cultured at 37°C for 24h anaerobic, and then transferred to fresh MRS liquid medium (containing 0.05g / 100mL cysteine), cultured under the same conditions for 24h, centrifuged the cells at 6000g for 15min, washed the cells with 0.9g / 100mL saline, and then centrifuged them again at 6000g for 10min to obtain the cells, which were resuspended in 30% sucrose solution , frozen at -80°C for later use.

Embodiment 3

[0070] Example 3: Tolerance of Bifidobacterium breve CCFM1078 to simulated gastrointestinal fluids

[0071] 1. Tolerance of Bifidobacterium breve CCFM1078 to simulated gastric juice

[0072]The Bifidobacterium breve CCFM1078 obtained in Example 1 was inserted into the MRS liquid medium for anaerobic culture at 37°C for 18 hours, and the cells were collected by centrifugation. The collected cells were washed with physiological saline, and after the washing was completed, centrifuged again. Cells were collected, and the collected cells were resuspended in physiological saline containing 3 g / L pepsin with pH 3 (pH adjusted by HCl), and 0.1 mL of bacterial solution was taken to count the viable bacteria on the plate by pouring method as the bacterial solution. The original viable count of Bifidobacterium breve CCFM1078, the remaining bacterial solution was placed at 37 °C for anaerobic culture for 3 hours, and 0.1 mL of bacterial solution was taken to count the viable bacteria on ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a strain of Bifidobacterium breve that can relieve rheumatoid arthritis and its application, belonging to the technical field of microorganisms. The invention screened out a strain of Bifidobacterium breve CCFM1078, and the Bifidobacterium breve CCFM1078 has the effect of relieving rheumatoid arthritis, which is embodied in: significantly promoting the secretion of anti-inflammatory factor IL-10 by RAW264.7 cells; Joint thickness, clinical score, and morbidity in rheumatoid arthritis rats; significantly reduced serum pro-inflammatory cytokines TNFα and IL-1β in rheumatoid arthritis rats; significantly modulated feces in rheumatoid arthritis rats The content of short-chain fatty acids; significantly reduce the proportion of Th17 cells in the mesenteric lymph nodes of rheumatoid arthritis rats; significantly reduce the secretion of the pro-inflammatory factor IL-6 by synovial cells.

Description

technical field [0001] The invention relates to a Bifidobacterium breve that can relieve rheumatoid arthritis and its application, and belongs to the technical field of microorganisms. Background technique [0002] Rheumatoid Arthritis (RA) is a complex autoimmune disease characterized by joint synovitis, progression to cartilage and bone tissue destruction, and ultimately joint stiffness and dysfunction. The incidence of rheumatoid arthritis (Rheumatoid Arthritis, RA) is higher in females than in males, and higher in middle-aged and elderly people than in young children, and it shows a certain heredity. [0003] At present, in the treatment of rheumatoid arthritis, traditional drugs such as anti-rheumatic drugs, glucocorticoids, non-steroidal anti-inflammatory drugs, and some new biological agents are often used. These drugs all have limitations. For example, in the initial stage of the disease, traditional drugs are used clinically to limit the disease, but these drugs ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N1/20A23C9/12A23C13/16A23C15/06A23C15/12A23C15/16A23C17/02A23C19/032A23C19/06A23L11/50A23L13/40A23L29/00A23L33/135A61K35/745A61P19/02A61P29/00C12R1/01
CPCC12N1/20A23L33/135A23L13/45A23L29/065A23C9/1203A23C13/16A23C15/065A23C15/123A23C15/165A23C17/02A23C19/0323A23C19/062A61K35/745A61P19/02A61P29/00A23V2002/00C12R2001/01C12N1/205A23V2400/519A23V2200/30A23L2/02A23L2/382A23L2/52A23L33/40
Inventor 杨波陈卫樊哲新赵建新张灏
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap